JPMorgan lowered the firm’s price target on Ceribell (CBLL) to $17 from $21 and keeps an Overweight rating on the shares. The company reported another good “beat-and-raise” with tailwinds heading into 2026, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc. Receives Buy Rating Due to Strong Financial Performance and Strategic Growth Initiatives
- Ceribell, Inc. Reports Strong Q3 2025 Revenue Growth
- Ceribell, Inc. Receives Buy Rating from Josh Jennings Amid Strong Q3 Performance and Future Growth Potential
- Ceribell, Inc.: Strong Q3 Performance and Promising Growth Prospects Drive Buy Rating
- Ceribell raises FY25 revenue view to $87M-$89M from $85M-$88M